We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$319M
AUM Growth
+$70.9M
Cap. Flow
+$46.8M
Cap. Flow %
14.67%
Top 10 Hldgs %
84.89%
Holding
29
New
5
Increased
1
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$31.8M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$9.8M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$6.6M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
2
BYSI icon
BeyondSpring
BYSI
+$5.55M
3
ATRC icon
AtriCure
ATRC
+$1.92M
4
ACET icon
Adicet Bio
ACET
+$410K
5
OWLT icon
Owlet
OWLT
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 71.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
26
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-150,000
Closed -$16.1M
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q2 2023 Portfolio in Review

As of Q2 2023, Decheng Capital Management III (Cayman) held 29 positions worth $319M, up 29% from $248M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Decheng Capital Management III (Cayman) deployed $46.8M of net new capital in Q2 2023, opening 5 new positions and adding to 1 existing holding. Its largest new stake was ACELYRIN: 1,554,417 shares worth $32.5M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 79% a quarter earlier.

On the sell side, the largest reduction was Adicet Bio, an estimated $410K trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q2 2023 buy was ACELYRIN: 1,554,417 shares worth $32.5M.
  • Decheng Capital Management III (Cayman) added most to Zentalis Pharmaceuticals in Q2 2023, an estimated $6.6M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q2 2023 reduction was Adicet Bio, cutting an estimated $410K.
  • Decheng Capital Management III (Cayman) fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 85% of its $319M portfolio in Q2 2023.
  • Decheng Capital Management III (Cayman) opened 5 new positions and closed 4 in Q2 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value rose 29% quarter-over-quarter to $319M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q2 2023, filed 28 Jul 2023.